AbbVie's Parkinson's prospect hits again in phase 3, completing clean sweep to tee up FDA filing

AbbVie's Parkinson's prospect hits again in phase 3, completing clean sweep to tee up FDA filing

Source: 
Fierce Biotech
snippet: 

AbbVie has completed a hat trick of phase 3 wins for its Parkinson’s disease prospect tavapadon, teeing the drugmaker up to file for FDA approval in 2025.

The Big Pharma acquired the once-daily oral dopamine D1/D5 receptor partial agonist in its $8.7 billion takeover of Cerevel Therapeutics.